Design of new phenothiazine-thiadiazole hybrids via molecular hybridization approach for the development of potent antitubercular agents

dc.contributor.authorRamprasad, J.
dc.contributor.authorNayak, N.
dc.contributor.authorUdayakumar, U.
dc.date.accessioned2026-02-05T09:33:31Z
dc.date.issued2015
dc.description.abstractA new library of phenothiazine and 1,3,4-thiadiazole hybrid derivatives (5a-u) was designed based on the molecular hybridization approach and the molecules were synthesized in excellent yields using a facile single-step chloro-amine coupling reaction between 2-chloro-1-(10H-phenothiazin-10-yl)ethanones and 2-amino-5-subsituted-1,3,4-thiadiazoles. The compounds were evaluated for their in vitro inhibition activity against Mycobacterium tuberculosis H37Rv (MTB). Compounds 5g and 5n were emerged as the most active compounds of the series with MIC of 0.8 ?g/mL (?1.9 ?M). Also, compounds 5a, 5b, 5c, 5e, 5l and 5m (MIC = 1.6 ?g/mL), and compounds 5j, 5k and 5o (MIC = 3.125 ?g/mL) showed significant inhibition activity. The structure-activity relationship demonstrated that an alkyl (methyl/npropyl) or substituted (4-methyl/4-Cl/4-F) phenyl groups on the 1,3,4-thiadiazole ring enhance the inhibition activity of the compounds. The cytotoxicity study revealed that none of the active molecules are toxic to a normal Vero cell line thus proving the lack of general cellular toxicity. Further, the active molecules were subjected to molecular docking studies with target enzymes InhA and CYP121. © 2015 Elsevier Masson SAS. All rights reserved.
dc.identifier.citationEuropean Journal of Medicinal Chemistry, 2015, 106, , pp. 75-84
dc.identifier.issn2235234
dc.identifier.urihttps://doi.org/10.1016/j.ejmech.2015.10.035
dc.identifier.urihttps://idr.nitk.ac.in/handle/123456789/26184
dc.publisherElsevier Masson SAS 62 rue Camille Desmoulins Issy les Moulineaux Cedex 92442
dc.subject1 (2 chloro 10h phenothiazin 10 yl) 2 [2 imino 5 (4 tolyl) 1,3,4 thiadiazol 3(2h) yl] ethanone
dc.subject1 (2 chloro 10h phenothiazin 10 yl) 2 [2 imino 5 methyl 1, 3, 4 thiadiazol 3(2h)yl]ethanone
dc.subject1 (2 chloro 10h phenothiazin 10 yl) 2 [2 imino 5 propyl 1,3,4 thiadiazol 3(2h) yl]ethanone
dc.subject1 (2 chloro 10h phenothiazin 10 yl) 2 [5 (3,4 dimethoxyphenyl) 2 imino 1,3,4-thiadiazol 3(2h) yl]ethanone
dc.subject1 (2 chloro 10h phenothiazin 10 yl) 2 [5 (4 fluorophenyl) 2 imino 1, 3, 4 thiadiazol 3(2h) yl]ethanone
dc.subject1 (2 chloro 10h phenothiazin 10 yl) 2 [5(4 chlorophenyl) 2 imino 1,3,4 thiadiazol 3(2h) yl] ethanone
dc.subject1,3,4 thiadiazole derivative
dc.subject2 (2 imino 5 propyl 1,3,4 thiadiazol 3(2h) yl] 1 (10h phenothiazin 10 yl) ethanone
dc.subject2 (2 imino 5 propyl 1,3,4 thiadiazol 3(2h) yl] 1 [2 (trifluoromethyl) 10h phenothiazin 10 yl] ethanone
dc.subject2 amino 5 subsituted 1,3,4 thiadiazole derivative
dc.subject2 chloro 1 (10h phenothiazin 10 yl)ethanone derivative
dc.subject2 [2 imino 5 (4 tolyl) 1,3,4 thiadiazol 3(2h) yl] 1 [2 (trifluoromethyl) 10h phenothiazin 10 yl] ethanone
dc.subject2 [2 imino 5 methyl 1,3,4 thiadiazol 3(2h) yl] 1 (10h phenothiazin 10 yl)ethanone
dc.subject2 [2 imino 5 methyl 1,3,4 thiadiazol 3(2h) yl] 1 [2 (trifluoromethyl) 10h phenothiazin 10 yl] ethanone
dc.subject2 [5 (3,4 dimethoxyphenyl) 2 imino 1,3,4-thiadiazol 3(2h) yl] 1 (10h phenothiazin 10 yl) ethanone
dc.subject2 [5 (3,4 dimethoxyphenyl) 2 imino 1,3,4-thiadiazol 3(2h) yl] 1 [2 (trifluoromethyl) 10h phenothiazin 10 yl]ethanone
dc.subject2 [5 (4 chlorophenyl) 2 imino 1,3,4 thiadiazol 3(2h) yl] 1 (10h phenothiazin 10 yl)ethanone
dc.subject2 [5 (4 chlorophenyl) 2 imino 1,3,4 thiadiazol 3(2h) yl] 1 [2 (trifluoromethyl) 10h phenothiazin 10 yl]ethanone
dc.subject2 [5 (4 fFluorophenyl) 2 imino 1,3,4 thiadiazol 3(2h) yl]1 (10h phenothiazine 10 yl] ethanone
dc.subject2 [5 (4 fluorophenyl) 2 imino 1,3,4 thiadiazol 3(2H) yl] 1 (10h phenothiazin 10 yl) ethanone
dc.subject2 [5 (4 fluorophenyl) 2 imino 1,3,4 thiadiazol 3(2h) yl] 1 [2 (trifluoromethyl) 10h phenothiazin 10 yl] ethanone
dc.subject2[(2 imino 5 para tolyl 1,3,4 thiadiazol 3(2h) yl] 1 (10h phenothiazin 10 yl) ethanone
dc.subjectciprofloxacin
dc.subjectethambutol
dc.subjectisoniazid
dc.subjectphenothiazine derivative
dc.subjectstreptomycin
dc.subjectthiadiazole derivative
dc.subjecttuberculostatic agent
dc.subjectunclassified drug
dc.subjectunindexed drug
dc.subjectphenothiazine
dc.subjectanimal cell
dc.subjectantibacterial activity
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectcytotoxicity
dc.subjectdrug design
dc.subjectdrug synthesis
dc.subjectin vitro study
dc.subjectminimum inhibitory concentration
dc.subjectmolecular docking
dc.subjectmolecular hybridization
dc.subjectMycobacterium tuberculosis
dc.subjectnonhuman
dc.subjectstructure activity relation
dc.subjectVero cell line
dc.subjectanimal
dc.subjectcell survival
dc.subjectchemical structure
dc.subjectchemistry
dc.subjectChlorocebus aethiops
dc.subjectdose response
dc.subjectdrug effects
dc.subjectEscherichia coli
dc.subjectmicrobial sensitivity test
dc.subjectPseudomonas aeruginosa
dc.subjectStaphylococcus aureus
dc.subjectsynthesis
dc.subjectAnimals
dc.subjectAntitubercular Agents
dc.subjectCell Survival
dc.subjectCercopithecus aethiops
dc.subjectDose-Response Relationship, Drug
dc.subjectDrug Design
dc.subjectMicrobial Sensitivity Tests
dc.subjectMolecular Docking Simulation
dc.subjectMolecular Structure
dc.subjectPhenothiazines
dc.subjectStructure-Activity Relationship
dc.subjectThiadiazoles
dc.subjectVero Cells
dc.titleDesign of new phenothiazine-thiadiazole hybrids via molecular hybridization approach for the development of potent antitubercular agents

Files

Collections